Market Overview

UPDATE: Stifel Nicolaus Initiates Medtronic at Hold on Valuation

Related MDT
Medtronic, Inc.: Medtronic Drug-Coated Balloon for Peripheral Artery Disease Tops Standard Balloon Angioplasty in Landmark
UPDATE: Bank Of America Reiterates On Medtronic Post COV Financing
JPM Denies Report of Second Hack Attack (Fox Business)

Stifel Nicolaus initiated coverage on Medtronic (NYSE: MDT) with a Hold rating.

Stifel Nicolaus commented, "We are initiating coverage of Medtronic, Inc. (MDT) with a Hold rating on the shares. Fair-to-reasonable valuation for the stock and lack of dramatic upside drivers keep us on the sidelines for the moment. With approximately 50% of Medtronic's business still in pressured "no growth" markets (Cardiac Rhythm Management and Spine) and limited room for further operating margin expansion, we suspect Medtronic's 10.8x forward P/E multiple is unlikely to expand significantly on a relative basis. With MDT shares already trading at the high end of the industry peer group on an EV/EBITDA basis, we prefer to wait for a better entry point on the shares."

Medtronic closed at $41.10 on Monday.

Latest Ratings for MDT

DateFirmActionFromTo
Dec 2014Bank of AmericaMaintainsBuy
Nov 2014WedbushMaintainsNeutral
Nov 2014JefferiesMaintainsBuy

View More Analyst Ratings for MDT
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (MDT)

Around the Web, We're Loving...

Get Benzinga's Newsletters